Latest news with #Genmab
Business Insider
4 days ago
- Business
- Business Insider
Genmab price target lowered to DKK 1,500 from DKK 1,700 at JPMorgan
JPMorgan lowered the firm's price target on Genmab (GMAB) to DKK 1,500 from DKK 1,700 and keeps a Neutral rating on the shares. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
6 days ago
- Business
- Yahoo
Commit Biologics appoints leading industry experts to newly formed Scientific Advisory Board
Industry and scientific experts in molecular biology, immunology and antibody research appointed to help develop Commit's BiCE™ technology platform to treat autoimmune disease and cancer Leading antibody expert Janine Schuurman to co-chair Commit's Scientific Advisory Board alongside Commit's CEO Mikkel Wandahl Pedersen Joined by Paul Parren, Gavin Thurston, Susan Kalled, and Esper Boel on the Scientific Advisory Board AARHUS, Denmark, June 4, 2025 /PRNewswire/ -- Commit Biologics ("Commit"), a pioneer in the activation of the complement system to treat autoimmune disease and cancer, today announces the formation of its Scientific Advisory Board (SAB) with the appointment of five leading industry and scientific experts. The newly formed board will be co-chaired by leading antibody expert Janine Schuurman, PhD, and Commit's CEO Mikkel Wandahl Pedersen. They are being joined by Professor of Molecular Immunology, former Genmab SVP and serial biotech entrepreneur Paul Parren, PhD; former Regeneron SVP of Oncology Research Gavin Thurston, PhD; esteemed immunologist Susan Kalled, PhD, who has previously worked as CSO at both Dianthus Therapeutics and Compass Therapeutics; and molecular biologist Esper Boel, PhD, previously CTO at Symphogen and Corporate Vice President and Head of Biotechnology at Novo Nordisk. The SAB will provide constructive feedback to Commit's management team and Board of Directors as the Company further develops its Bispecific Complement Engager (BiCE™) technology platform. Mikkel Wandal Pedersen, PhD, Chief Executive Officer of Commit Biologics, said: "Forming Commit's Scientific Advisory Board is a pivotal step in our mission to bring first-in-class complement engager therapeutics to patients. I am very pleased that we have been able to gather such an accomplished group of people with deep immunology and drug-development experience. I am confident that their collective insight will sharpen our strategy and accelerate advancement of our pipeline." Scientific Advisory Board Janine Schuurman, PhD, is a molecular immunologist who has contributed to six FDA- and EMA-approved therapeutic antibodies, including four therapeutics from Genmab's DuoBody bispecific antibody platform. She spent 22 years at Genmab, most recently as Senior Vice President, Head of Antibody Research and Technology, propelling the discovery and development of investigational therapies to treat cancer and other diseases. Besides serving as an independent biotech consultant providing expert advice to a number of life sciences companies, Janine also serves as board member and President of The Antibody Society. Gavin Thurston, PhD, is a highly experienced R&D executive and scientific leader with over 20 years of experience in oncology research. He previously served as Senior Vice President of Oncology Research at Regeneron, where he played a pivotal role in the successful clinical development of LIBTAYO® and the ongoing late-stage clinical testing of seven other antibodies and bispecific antibodies. Following his time at Regeneron, Dr Thurston has been involved in a number of consultancy projects with antibody therapeutic companies. Paul Parren, PhD, is a molecular immunologist who has contributed to nine FDA- and EMA-approved therapeutic antibodies, including four therapeutics from Genmab's DuoBody bispecific antibody platform. He has spent over 25 years translating antibody knowledge into innovative therapies including 15 years at Genmab, where he headed preclinical R&D. More recently he was head of R&D at LAVA Therapeutics NV, which obtained a NASDAQ listing during his five-year tenure. He currently serves as Professor of Molecular Immunology at Leiden University Medical Centre in The Netherlands, is chairman of the board of The Antibody Society, provides expert advice and is a co-founder and CSO of Gyes BV and its two spin-out companies. Susan Kalled, PhD, is an immunologist with over 25 years of experience spanning early discovery research, clinical drug development and strategic partnerships in the areas of autoimmunity & inflammation, rare diseases and immuno-oncology. Previously she was CSO at Dianthus Therapeutics and Compass Therapeutics. As Vice President of Biology at Q32 Bio, Kalled established the founding research team and played a key role in shaping the company's complement and immunology-focused pipeline. She has also held a number of leadership positions at Biogen and Shire, driving scientific strategy. She currently serves as a scientific strategist and advisor to both early start-ups and established companies. Esper Boel, PhD, is a molecular biologist with 40 years of experience in international biopharmaceutical R&D. He spent 34 years at Novo Nordisk, most recently as Corporate Vice President and Head of Biotechnology. During this time, he was responsible for building and heading a 240+ employee international protein-biotechnology organisation and he established the first international biopharmaceutical R&D centre in Beijing, China. Following his time at Novo Nordisk, he has served as a member of executive teams, on boards and as a senior advisor for a number of high-profile immunology-based companies. Commit Biologics is advancing development of its BiCE™ technology to redefine the treatment of autoimmune disease and cancer. This novel platform is designed to potently activate the complement system to induce highly selective killing of cells implicated in autoimmune disease or tumour cells. BiCE™ uses single domain antibodies that bind to the complement protein C1q, consequently directing the complement system in a highly targeted way against cells of interest. The complement system is part of the body's immune system that has previously been largely untapped therapeutically. The activation of the classical complement pathway, which has a role in health for pathogen defence, begins with the engagement of C1q to antibodies that coat the cell surface, thus initiating multiple effector functions that lead to cell killing. About Commit BiologicsCommit Biologics (Commit) is a pioneer in activating the complement system to kill specific target cells, with applications in autoimmune diseases and cancer. Spun out of Aarhus University, and building on more than three decades of research, Commit's Bispecific Complement Engaging (BiCE™) platform can supercharge a conventional monoclonal antibody to activate the complement system more effectively. This is achieved by combining single domain antibodies that engage C1q, the starting point for the complement activation cascade, with an antibody that binds to a cellular target. The modular approach of the BiCE™ technology can be used to develop therapeutics across multiple tumour-associated antigens and immune cell targets. Complement is a largely untapped aspect of the body's natural immune system that leverages both the direct cytolytic activity of complement along with its ability to recruit and activate both innate and adaptive immune cells – a new approach to killing cells which can be used in combination or on a standalone basis. Commit is backed by major investors including Novo Holdings, Bioqube Ventures and Korys. About the complement systemThe complement system is part of the body's immune system that has previously been largely untapped therapeutically. The activation of the classical complement pathway, which has a role in health for pathogen defence, begins with the engagement of C1q to antibodies that coat the cell surface and ends with the activation of a cytolytic complement complex directly leading to cell lysis. However, current monoclonal antibodies developed for therapeutic purposes have structural restraints that hinder effective engagement to C1q, thus limiting complement mediated cytotoxicity and other complement mediated effector functions. This, plus the presence of natural cell bound complement inhibitors that are often upregulated in disease settings, and low target densities, make conventional therapeutic antibodies poor complement activators. Commit's BiCE™ technology was developed to overcome these barriers, to harness the power of the complement system and direct it towards tumour and immune cells for therapeutic applications. Unleashing this power in a highly targeted way with Commit's technology potentially allows for a broad therapeutic index and the development of highly effective treatments. View original content: SOURCE Commit Biologics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
Why Genmab Stock Smashed It on Monday
The company's uterine cancer drug is advancing in its development. Management is also assertively conducting a share buyback program. 10 stocks we like better than Genmab A/s › On a generally upbeat Monday for the stock market, investors weren't only buying into U.S. companies. Quite a few of them also piled into the American Depositary Receipts (ADRs) of Danish biotech Genmab (NASDAQ: GMAB), on the back of encouraging news from the laboratory. Management's disclosure of the status of a shareholder-pleasing initiative also helped boost sentiment. The price of those ADRs rose by almost 4% as a result -- quite a distance higher than the S&P 500's (SNPINDEX: ^GSPC) 0.4% advance. On Monday morning, Genmab announced a set of phase 1/2 clinical trial results for its rinatabart sesutecan (Rina-S) drug, which it's developing for a type of uterine cancer. The company said the drug showed a confirmed objective response rate of 50% in patients with an advanced form of the cancer who had received treatment with other medications. In its press release detailing the results, Genmab quoted study investigator Ira Winer as saying that the results "demonstrate encouraging data with Rina-S in this patient population and support its further development as a potential therapy for patients with advanced and recurrent endometrial cancer." The company added that, with this at its back, it aims to continue the development of the drug. Separately, Genmab updated investors about its current share buyback program, which authorized the repurchase of up to 2.2 million shares of its Europe-listed stock by July 10 of this year. The company was quite an aggressive buyer, snapping up just under 2.08 million shares for a total of slightly more than 2.7 billion Danish kronor ($411 million). Taken together, those two news items suggest that Genmab is on the right path with its development activities, and believes in its pipeline. The proof with Rina-S, of course, will come with later-stage clinical trials. However, at this point, the company's future looks promising, and the bullish market reaction feels justified. Before you buy stock in Genmab A/s, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Genmab A/s wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Genmab A/s. The Motley Fool has a disclosure policy. Why Genmab Stock Smashed It on Monday was originally published by The Motley Fool
Yahoo
30-05-2025
- Business
- Yahoo
Genmab price target lowered to DKK 2,000 from DKK 2,300 at RBC Capital
RBC Capital lowered the firm's price target on Genmab (GMAB) to DKK 2,000 from DKK 2,300 and keeps an Outperform rating on the shares. The firm is updating its model after Q1 results, with minimal underlying changes but now incorporating an updated USD-DKK exchange rate which significantly lowers royalty income on U.S. sales in DKK terms, the analyst tells investors in a research note. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on GMAB: Disclaimer & DisclosureReport an Issue Genmab Executes Share Buy-back Transactions in May 2025 Genmab's Promising Rina-S Developments Drive Buy Rating Amid Strong Initial Study Results Genmab's Rina-S: Promising Efficacy and Strategic Growth Potential in Endometrial Cancer Treatment Genmab A/S Updates Articles to Enhance Capital Flexibility Genmab Announces Capital Increase Following Employee Warrant Exercise Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
29-05-2025
- Business
- Globe and Mail
Central Nervous System Tumors Pipeline Appears Robust With 13+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's ' Central Nervous System Tumors Pipeline Insight 2025 ' report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Central Nervous System Tumors pipeline landscape. It covers the Central Nervous System Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Central Nervous System Tumors Pipeline. Dive into DelveInsight's comprehensive report today! @ Central Nervous System Tumors Pipeline Outlook Key Takeaways from the Central Nervous System Tumors Pipeline Report In May 2025, Genmab announced a study will be conducted in two parts: Part 1 (dose-finding) and Part 2 (randomization). The main purpose is to assess the safety and clinical activity of GEN1042 in combination with radiotherapy or GEN1042 in combination with radiotherapy and pembrolizumab as a treatment option for participants with metastatic solid tumors. In May 2025, Stemline Therapeutics Inc. announced a study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was designed to select the recommended phase 2 dose and is followed by an ongoing phase 2 evaluation of elacestrant in combination with abemaciclib in patients with active brain metastases from ER-positive, HER-2 negative breast cancer. In May 2025, Hoffmann-La Roche organized a study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available. DelveInsight's Central Nervous System Tumors Pipeline report depicts a robust space with 13+ active players working to develop 13+ pipeline therapies for Central Nervous System Tumors treatment. Promising Central Nervous System Tumors Companies such as Shandong New Time Pharmaceutical, PIQUR Therapeutics, Ono Pharmaceutical, Janssen, LP, Kazia Therapeutics, Beijing InnoCare Pharma Tech, Celltrion, Bristol Myers Squibb, AstraZeneca, Novartis, Prelude Therapeutics, Kite, A Gilead Company, Celgene and others. The leading Central Nervous System Tumors Pipeline Therapies such as Tozuleristide, Bevacizumab, Temozolomide, Pomalidomide, Niraparib, GNC-038, Pamiparib, Thalidomide and others. Stay ahead with the most recent pipeline outlook for Central Nervous System Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Central Nervous System Tumors Treatment Drugs Central Nervous System Tumors Emerging Drugs Profile F520: Shandong New Time Pharmaceutical F 520 is a humanized monoclonal antibody targeting programmed cell death 1 receptor antagonists being developed by Shandong New Time Pharmaceutical. The drug is being investigated in Phase II stage of development for the treatment of patients with Primary and secondary Central Nervous System Lymphoma. Tirabrutinib: Ono Pharmaceuticals Velexbru, discovered and developed by ONO, is a highly selective, oral BTK inhibitor and has been developed for the treatment in patients with B-cell tumors and autoimmune diseases in Japan. B-cell receptor (BCR) signaling plays a core role in the survival, activation, proliferation, maturation and differentiation of B-cell lymphocyte. In Japan, Velexbru was approved in March 2020 and launched in May 2020 for the treatment of relapsed or refractory primary central nervous system lymphoma (PCNSL). Ono Pharmaceutical has initiated a Phase II clinical trial in US with Velexbru in patients with primary central nervous system lymphoma. The Central Nervous System Tumors Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Central Nervous System Tumors with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Central Nervous System Tumors Treatment. Central Nervous System Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Central Nervous System Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Central Nervous System Tumors market Explore groundbreaking therapies and clinical trials in the Central Nervous System Tumors Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Central Nervous System Tumors Drugs Central Nervous System Tumors Companies Shandong New Time Pharmaceutical, PIQUR Therapeutics, Ono Pharmaceutical, Janssen, LP, Kazia Therapeutics, Beijing InnoCare Pharma Tech, Celltrion, Bristol Myers Squibb, AstraZeneca, Novartis, Prelude Therapeutics, Kite, A Gilead Company, Celgene and others. Central Nervous System Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical Molecule Type Central Nervous System Tumors Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Unveil the future of Central Nervous System Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Central Nervous System Tumors Market Drivers and Barriers Scope of the Central Nervous System Tumors Pipeline Report Coverage- Global Central Nervous System Tumors Companies- Shandong New Time Pharmaceutical, PIQUR Therapeutics, Ono Pharmaceutical, Janssen, LP, Kazia Therapeutics, Beijing InnoCare Pharma Tech, Celltrion, Bristol Myers Squibb, AstraZeneca, Novartis, Prelude Therapeutics, Kite, A Gilead Company, Celgene and others. Central Nervous System Tumors Pipeline Therapies- Tozuleristide, Bevacizumab, Temozolomide, Pomalidomide, Niraparib, GNC-038, Pamiparib, Thalidomide and others. Central Nervous System Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Central Nervous System Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Central Nervous System Tumors Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Central Nervous System Tumors Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Central Nervous System Lymphoma: Overview Pipeline Therapeutics Therapeutic Assessment Late Stage Products (Phase III) Drug Name: Company Name Drug profiles in the detailed report….. Mid Stage Products (Phase II) F520: Shandong New Time Pharmaceutical Drug profiles in the detailed report….. Early stage products (Phase I) PRT811: Prelude Therapeutics Drug profiles in the detailed report….. Inactive Products Central Nervous System Lymphoma Key Companies Central Nervous System Lymphoma Key Products Central Nervous System Lymphoma- Unmet Needs Central Nervous System Lymphoma- Market Drivers and Barriers Central Nervous System Lymphoma- Future Perspectives and Conclusion Central Nervous System Lymphoma Analyst Views Central Nervous System Lymphoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
